Login to Your Account



EUSA Swings an Ideal Exit with the $700M Acquisition by Jazz

By Nuala Moran and Catherine Shaffer
Staff Writers

Monday, April 30, 2012

The privately held UK specialty oncology firm EUSA Pharma Ltd. is to be acquired by Jazz Pharmaceuticals Inc. in a $700 million cash deal that is motivated by the early commercial success of EUSA's Erwinaze treatment for pediatric acute lymphoblastic leukemia (ALL), approved by the FDA in November 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription